Chronic Hyperuricemia and Silent MSU Crystal Seeding
Urate stays above saturation while crystals seed silently in tissue.
- 6.8 mg/dL: Solubility threshold (plasma MSU saturation limit)
- ~20%: Hyperuricemia prevalence (of US adults)
- 3–42 yr: Time to first tophus (highly variable onset)
- up to 30%: Crystals seen on US (asymptomatic hyperuricemia)
Urate solubility and supersaturation
Serum urate above 6.8 mg/dL exceeds plasma solubility.
Subclinical crystal seeding in joints
Needle-shaped MSU crystals accumulate before any symptoms.
Visible Tophus Nucleation at Joint and Soft Tissue Sites
Crystal aggregates coalesce into a first visible nodule.
- 1st MTP, ear, elbow: Common sites (joint and soft tissue)
- ~5 mm: Median size at detection (palpable nodule)
- Sustained supersaturation: Growth trigger (above 6.8 mg/dL)
- ~12%: Palpable tophi at 10 yr (of untreated gout)
Nucleation core and fibrous capsule
A dense crystal core forms a fibrovascular capsule.
Chronic inflammatory rim formation
Macrophages and giant cells wall off the deposit.
Tophus Growth Under Continued Hyperuricemia
Continued high urate drives steady chalky-mass expansion.
- ~1–5 mm/yr: Growth rate (untreated) (diameter increase)
- Elevated: Bone erosion risk (periarticular joint damage)
- Rises with size: Flare frequency (acute inflammatory episodes)
- Often irreversible: Structural damage (without urate control)
Layered crystal accretion mechanics
New crystal layers deposit fastest at the surface.
Periarticular bone erosion
Expanding mass compresses and erodes adjacent bone.
Sustained Urate-Lowering Therapy Initiated
Sustained therapy pushes serum urate below saturation.
- <5 mg/dL: Target urate (tophaceous) (below solubility margin)
- Allopurinol, febuxostat: First-line agents (xanthine oxidase inhibitors)
- Transient rise: Early flare risk (crystal mobilization phase)
- ~4–8 wk: Time to urate plateau (with dose titration)
Xanthine oxidase inhibition mechanism
Lower urate production shifts the crystal equilibrium.
Flare prophylaxis during initiation
Low-dose colchicine covers the early mobilization period.
Progressive Tophus Shrinkage and Dissolution
Macrophages resorb the tophus over months to years.
- Months to years: Dissolution timescale (depends on undersaturation)
- ~50% by 5 yr: Full resolution reported (with sustained low urate)
- Depth below 6.8 mg/dL: Key driver (undersaturation magnitude)
- Ultrasound / DECT: Monitoring tool (serial volume tracking)
Crystal dissolution kinetics
Undersaturated plasma slowly redissolves surface crystals first.
Macrophage-mediated clearance
Giant cells phagocytose and clear liberated crystal debris.